<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145039</url>
  </required_header>
  <id_info>
    <org_study_id>2013OC116</org_study_id>
    <secondary_id>MT2013-33C</secondary_id>
    <nct_id>NCT02145039</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases</brief_title>
  <official_title>Reduced Intensity Conditioning (RIC) and Transplantation of HLA(Human Leukocyte Antigen)-Haploidentical Related Bone Marrow (Haplo-BM) For Patients With Hematologic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant
      (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen, consisting of
      fludarabine, cyclophosphamide and low dose total body irradiation (TBI), is designed for the
      treatment of patients with advanced and/or high risk diseases.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Replaced by another study.
  </why_stopped>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2 Year Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients that survive 2 years post-transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Hematopoietic Engraftment</measure>
    <time_frame>42 days</time_frame>
    <description>Engraftment is defined as absolute neutrophil count (ANC) ≥ 5 X 10^8/L for 3 consecutive measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Chimerism</measure>
    <time_frame>100 days</time_frame>
    <description>Number of patients with chimerism at day 100, 6 months and 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Experiencing Acute Graft-versus-host Disease by 100 Days</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Experiencing Chronic Graft-versus-host Disease by 1 Year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Experiencing Transplant Related Mortality (TRM)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Acute Leukemias</condition>
  <condition>Burkitt's Lymphoma</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Haploidentical stem cell transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.</description>
    <arm_group_label>Haploidentical stem cell transplant</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.</description>
    <arm_group_label>Haploidentical stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>TBI 200cGy on day -1 before transplant.</description>
    <arm_group_label>Haploidentical stem cell transplant</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haploidentical stem cell transplant</intervention_name>
    <description>Non-T-cell depleted bone marrow infusion</description>
    <arm_group_label>Haploidentical stem cell transplant</arm_group_label>
    <other_name>HSCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be &lt;75 years old with no 7/8 or 8/8 HLA-matched sibling donor

          -  One or more potential related mismatched donors (e.g. biologic parent (s) or siblings
             (full or half) or children). Low resolution using DNA based typing at HLA-A, -B and
             -DRB1 for potential haploidentical donors is required.

          -  All diseases listed below are advanced hematologic malignancies not curable by
             conventional chemotherapy. Responses to conventional treatment range from zero to 30%
             but are typically short lived.

               -  Acute Lymphoblastic Leukemia (ALL) in first complete remission (CR1) that is NOT
                  considered favorable-risk.

               -  Acute Myelogenous Leukemia (AML) in first complete remission (CR1) that is NOT
                  considered as favorable-risk.

               -  Acute Leukemias in 2nd or subsequent CR

               -  Biphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR,
                  adult T-cell leukemia/lymphoma in first or subsequent CR

               -  Burkitt's lymphoma in CR2 or subsequent CR

               -  Natural killer cell malignancies after response to initial therapy

               -  Chronic myelogenous leukemia: all types except refractory blast crisis.

               -  Large-cell lymphoma, Hodgkin lymphoma and multiple myeloma with chemotherapy
                  sensitive disease that has failed or patients who are ineligible for an
                  autologous transplant.

               -  Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone
                  B-cell lymphoma, follicular lymphoma, which have progressed within 12 months of
                  achieving a partial or complete remission.

               -  Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are
                  eligible after initial therapy if chemotherapy sensitive.

               -  Refractory leukemia or MDS These patients may be taken to transplant in aplasia
                  after induction or re-induction chemotherapy or radiolabeled antibody.

               -  Bone marrow failure syndromes, except for Fanconi Anemia

               -  Myeloproliferative syndromes

          -  Adequate organ function is defined as:

               -  Cardiac: Absence of decompensated congestive heart failure, or uncontrolled
                  arrhythmia and left ventricular ejection fraction &gt; 35%. For children that are
                  not able to cooperate with multigated acquisition scan (MUGA) and
                  echocardiography, such should be clearly stated in the physician's note

               -  Pulmonary: Diffusing capacity of lung for carbon monoxide (DLCO) &gt; 30% predicted,
                  and absence of O2 requirements. For children that are not able to cooperate with
                  pulmonary function tests (PFTs), a pulse oximetry with exercise should be
                  attempted. If nether test can be obtained it should be clearly stated in the
                  physician's note.

               -  Liver: Transaminases &lt; 5 x upper limit of normal and bilirubin &lt; 3 x upper limit
                  of normal

               -  Renal: serum creatinine &lt; 2.0 mg/dl (adults) or glomerular filtration rate (GFR)
                  &gt;40 mL/min/1.73m2 (peds). Patients with a creatinine &gt; 1.2 mg/dl or a history of
                  renal dysfunction must have glomerular filtration rate (GFR) &gt; 40 mL/min/1.73m2.

               -  Adequate performance status is defined as Karnofsky score ≥ 60% (&gt; 16 years of
                  age) or Lansky score ≥ 50 (pediatrics)

          -  If recent mold infection e.g. Aspergillus - must have minimum of 30 days of
             appropriate treatment before bone marrow transplant (BMT) and infection controlled and
             be cleared by Infectious Disease.

          -  Second BMT: Must be &gt; 3 months after prior myeloablative transplant.

          -  Patients must be ineligible for autologous transplantation due to prior autologous
             transplant, an inadequate autologous stem cell harvest, inability to withstand a
             myeloablative preparative regimen, or clinically aggressive/high risk disease.

          -  Patients are eligible for transplantation if there is no evidence of progressive
             disease by imaging modalities or biopsy. Persistent PET activity, though possibly
             related to lymphoma, is not an exclusion criterion in the absence of CT changes
             indicating progression.

          -  Patients with stable disease are eligible for transplantation if the largest residual
             nodal mass is &lt; 5 cm (approximately). For patients who have responded to preceding
             therapy, the largest residual mass must represent a 50% reduction and be &lt; 7.5 cm
             (approximately).

          -  Voluntary written consent (adult or parental/guardian)

        Exclusion Criteria:

          -  Available and clinically suitable 5-6/6 HLA-A, B, DRB1 matched sibling donor

          -  Pregnant or breastfeeding

          -  Evidence of HIV infection or known HIV positive serology

          -  Current active serious infection

          -  Unless in post-chemotherapy and radioimmunoconjugated antibody induced aplasia, when
             he/she would be eligible, patients with acute leukemia in morphologic relapse/
             persistent disease defined as &gt; 5% blasts in normocellular bone marrow OR any % blasts
             if blasts have unique morphologic markers (e.g. Auer rods) or associated cytogenetic
             markers that allows morphologic relapse to be distinguished are not eligible.

          -  Chronic myeloid leukemia (CML) in refractory blast crisis

          -  Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressive on
             salvage therapy. Stable disease is acceptable to move forward provided it is
             non-bulky.

          -  active central nervous system malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Brunstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <results_first_submitted>October 10, 2019</results_first_submitted>
  <results_first_submitted_qc>December 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 26, 2019</results_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia (ALL)</keyword>
  <keyword>Acute Myelogenous Leukemia (AML)</keyword>
  <keyword>Burkitt's lymphoma</keyword>
  <keyword>Natural killer cell malignancies</keyword>
  <keyword>Chronic myelogenous leukemia</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>Large-cell lymphoma</keyword>
  <keyword>Hodgkin lymphoma</keyword>
  <keyword>Multiple myeloma</keyword>
  <keyword>Chronic lymphocytic leukemia (CLL)</keyword>
  <keyword>Small lymphocytic lymphoma (SLL)</keyword>
  <keyword>Marginal zone B-cell lymphoma</keyword>
  <keyword>Follicular lymphoma</keyword>
  <keyword>Lymphoplasmacytic lymphoma</keyword>
  <keyword>Mantle-cell lymphoma</keyword>
  <keyword>Prolymphocytic leukemia</keyword>
  <keyword>Refractory leukemia</keyword>
  <keyword>Myelodysplastic syndrome (MDS)</keyword>
  <keyword>Bone marrow failure syndromes</keyword>
  <keyword>Myeloproliferative syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 29, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT02145039/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Haploidentical Stem Cell Transplant</title>
          <description>This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
Fludarabine: Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
Cyclophosphamide: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
Total Body Irradiation: TBI 200cGy (centigray) on day -1 before transplant.
Haploidentical stem cell transplant: Non-T-cell depleted bone marrow infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Haploidentical Stem Cell Transplant</title>
          <description>This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
Fludarabine: Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
Cyclophosphamide: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
Total Body Irradiation: TBI 200cGy on day -1 before transplant.
Haploidentical stem cell transplant: Non-T-cell depleted bone marrow infusion</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>2 Year Survival</title>
        <description>Percentage of patients that survive 2 years post-transplant</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Stem Cell Transplant</title>
            <description>This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
Fludarabine: Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
Cyclophosphamide: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
Total Body Irradiation: TBI 200cGy on day -1 before transplant.
Haploidentical stem cell transplant: Non-T-cell depleted bone marrow infusion</description>
          </group>
        </group_list>
        <measure>
          <title>2 Year Survival</title>
          <description>Percentage of patients that survive 2 years post-transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Hematopoietic Engraftment</title>
        <description>Engraftment is defined as absolute neutrophil count (ANC) ≥ 5 X 10^8/L for 3 consecutive measurements.</description>
        <time_frame>42 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Stem Cell Transplant</title>
            <description>This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
Fludarabine: Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
Cyclophosphamide: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
Total Body Irradiation: TBI 200cGy on day -1 before transplant.
Haploidentical stem cell transplant: Non-T-cell depleted bone marrow infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hematopoietic Engraftment</title>
          <description>Engraftment is defined as absolute neutrophil count (ANC) ≥ 5 X 10^8/L for 3 consecutive measurements.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Chimerism</title>
        <description>Number of patients with chimerism at day 100, 6 months and 1 year</description>
        <time_frame>100 days</time_frame>
        <population>Chimerism at 6 months and 1 year not evaluated</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Stem Cell Transplant</title>
            <description>This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
Fludarabine: Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
Cyclophosphamide: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
Total Body Irradiation: TBI 200cGy on day -1 before transplant.
Haploidentical stem cell transplant: Non-T-cell depleted bone marrow infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Chimerism</title>
          <description>Number of patients with chimerism at day 100, 6 months and 1 year</description>
          <population>Chimerism at 6 months and 1 year not evaluated</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Chimerism at day 100</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Chimerism at 6 months</title>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not available due to patient's death</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Chimerism at 1 year</title>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not available due to patient's death</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Experiencing Acute Graft-versus-host Disease by 100 Days</title>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Stem Cell Transplant</title>
            <description>This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
Fludarabine: Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
Cyclophosphamide: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
Total Body Irradiation: TBI 200cGy on day -1 before transplant.
Haploidentical stem cell transplant: Non-T-cell depleted bone marrow infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing Acute Graft-versus-host Disease by 100 Days</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Experiencing Chronic Graft-versus-host Disease by 1 Year</title>
        <time_frame>1 year</time_frame>
        <population>Data were not collected for this Outcome Measure as both participants died by the 6 month time point</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Stem Cell Transplant</title>
            <description>This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
Fludarabine: Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
Cyclophosphamide: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
Total Body Irradiation: TBI 200cGy on day -1 before transplant.
Haploidentical stem cell transplant: Non-T-cell depleted bone marrow infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing Chronic Graft-versus-host Disease by 1 Year</title>
          <population>Data were not collected for this Outcome Measure as both participants died by the 6 month time point</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Experiencing Transplant Related Mortality (TRM)</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Stem Cell Transplant</title>
            <description>This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
Fludarabine: Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
Cyclophosphamide: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
Total Body Irradiation: TBI 200cGy on day -1 before transplant.
Haploidentical stem cell transplant: Non-T-cell depleted bone marrow infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing Transplant Related Mortality (TRM)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years post-transplant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Haploidentical Stem Cell Transplant</title>
          <description>This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
Fludarabine: Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
Cyclophosphamide: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
Total Body Irradiation: TBI 200cGy on day -1 before transplant.
Haploidentical stem cell transplant: Non-T-cell depleted bone marrow infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Claudio Brunstein</name_or_title>
      <organization>University of Minnesota Cancer Center</organization>
      <phone>612-625-8942</phone>
      <email>bruns072@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

